Gilead Details Its HCV Dominance As AbbVie Seeks Meaningful Market Position
Executive Summary
Gilead holds a 90% market share in the U.S. hepatitis C market, with Harvoni capturing roughly 85% of the aggregate treatment population. AbbVie hopes an imminent Japanese approval and a second-generation regimen will boost its HCV business.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.